BR9914096A - Forma de dosagem oral, distinta, método para prevenir ou tratar distúrbio hipercinético de déficit de atenção ou depressão, uso de uma forma de dosagem oral distinta, e, método para tratar vìcio de produtos contendo nicotina - Google Patents
Forma de dosagem oral, distinta, método para prevenir ou tratar distúrbio hipercinético de déficit de atenção ou depressão, uso de uma forma de dosagem oral distinta, e, método para tratar vìcio de produtos contendo nicotinaInfo
- Publication number
- BR9914096A BR9914096A BR9914096-9A BR9914096A BR9914096A BR 9914096 A BR9914096 A BR 9914096A BR 9914096 A BR9914096 A BR 9914096A BR 9914096 A BR9914096 A BR 9914096A
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- oral dosage
- treat
- different oral
- depression
- Prior art date
Links
- 239000006186 oral dosage form Substances 0.000 title abstract 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title abstract 3
- 229960002715 nicotine Drugs 0.000 title abstract 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 3
- 206010012335 Dependence Diseases 0.000 title abstract 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 title abstract 2
- 230000006735 deficit Effects 0.000 title abstract 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 241000208125 Nicotiana Species 0.000 abstract 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 1
- 229960001126 alginic acid Drugs 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 239000000783 alginic acid Substances 0.000 abstract 1
- 150000004781 alginic acids Chemical class 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- OZGPVYJHWWPEFT-RGNHYFCHSA-N manifaxine Chemical compound C[C@@H]1N[C@H](C)CO[C@@]1(O)C1=CC(F)=CC(F)=C1 OZGPVYJHWWPEFT-RGNHYFCHSA-N 0.000 abstract 1
- 230000005586 smoking cessation Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"FORMA DE DOSAGEM ORAL DISTINTA, MéTODO PARA PREVENIR OU TRATAR DISTúRBIO HIPERCINéTICO DE DéFICIT DE ATENçãO OU DEPRESSãO, USO DE UMA FORMA DE DOSAGEM ORAL DISTINTA, E, MéTODO PARA TRATAR VìCIO DE PRODUTOS CONTENDO NICOTINA" Esta invenção fornece formas de dosagem oral distintas, tipicamente tabletes ou cápsulas, contendo (2S,3S,5R)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol ou um seu sal ou solvato fisiologicamente aceitável, ou um solvato de dito sal, e uma quantidade estabilizante eficaz de ácido algínico. Estas formas de dosagem são utilizáveis para impedir ou tratar distúrbio ou depressão hipercinética de déficit de atenção, ou no tratamento de vício de produtos contendo nicotina, especialmente produtos contendo tabaco, tal como auxiliando na cessação de fumar.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10211298P | 1998-09-28 | 1998-09-28 | |
| PCT/EP1999/007117 WO2000018406A1 (en) | 1998-09-28 | 1999-09-24 | Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9914096A true BR9914096A (pt) | 2001-07-31 |
Family
ID=22288187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9914096-9A BR9914096A (pt) | 1998-09-28 | 1999-09-24 | Forma de dosagem oral, distinta, método para prevenir ou tratar distúrbio hipercinético de déficit de atenção ou depressão, uso de uma forma de dosagem oral distinta, e, método para tratar vìcio de produtos contendo nicotina |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1117407A1 (pt) |
| JP (1) | JP2002525328A (pt) |
| KR (1) | KR20010075385A (pt) |
| CN (1) | CN1328459A (pt) |
| AR (1) | AR022673A1 (pt) |
| AU (1) | AU6087399A (pt) |
| BR (1) | BR9914096A (pt) |
| CA (1) | CA2345638A1 (pt) |
| CZ (1) | CZ20011142A3 (pt) |
| HU (1) | HUP0103459A2 (pt) |
| IL (1) | IL142054A0 (pt) |
| MA (1) | MA26693A1 (pt) |
| NO (1) | NO20011555L (pt) |
| PE (1) | PE20001087A1 (pt) |
| PL (1) | PL346877A1 (pt) |
| TR (1) | TR200100863T2 (pt) |
| WO (1) | WO2000018406A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7750100A (en) * | 1999-10-13 | 2001-04-23 | Glaxo Group Limited | Method for the treatment of obesity |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4597969A (en) * | 1982-04-05 | 1986-07-01 | Merck Sharp & Dohme | Stabilization of unstable drugs or food supplements |
| GB8924528D0 (en) * | 1989-10-31 | 1989-12-20 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
-
1999
- 1999-09-23 MA MA25782A patent/MA26693A1/fr unknown
- 1999-09-24 TR TR2001/00863T patent/TR200100863T2/xx unknown
- 1999-09-24 IL IL14205499A patent/IL142054A0/xx unknown
- 1999-09-24 KR KR1020017003874A patent/KR20010075385A/ko not_active Withdrawn
- 1999-09-24 PL PL99346877A patent/PL346877A1/xx unknown
- 1999-09-24 HU HU0103459A patent/HUP0103459A2/hu unknown
- 1999-09-24 BR BR9914096-9A patent/BR9914096A/pt not_active IP Right Cessation
- 1999-09-24 JP JP2000571924A patent/JP2002525328A/ja active Pending
- 1999-09-24 CA CA002345638A patent/CA2345638A1/en not_active Abandoned
- 1999-09-24 AU AU60873/99A patent/AU6087399A/en not_active Abandoned
- 1999-09-24 CN CN99813675A patent/CN1328459A/zh active Pending
- 1999-09-24 EP EP99947420A patent/EP1117407A1/en not_active Withdrawn
- 1999-09-24 WO PCT/EP1999/007117 patent/WO2000018406A1/en not_active Ceased
- 1999-09-24 AR ARP990104841A patent/AR022673A1/es unknown
- 1999-09-24 CZ CZ20011142A patent/CZ20011142A3/cs unknown
- 1999-09-27 PE PE1999000976A patent/PE20001087A1/es not_active Application Discontinuation
-
2001
- 2001-03-27 NO NO20011555A patent/NO20011555L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20011555D0 (no) | 2001-03-27 |
| CA2345638A1 (en) | 2000-04-06 |
| KR20010075385A (ko) | 2001-08-09 |
| MA26693A1 (fr) | 2004-12-20 |
| IL142054A0 (en) | 2002-03-10 |
| PL346877A1 (en) | 2002-03-11 |
| AR022673A1 (es) | 2002-09-04 |
| CZ20011142A3 (cs) | 2001-09-12 |
| PE20001087A1 (es) | 2000-10-20 |
| EP1117407A1 (en) | 2001-07-25 |
| NO20011555L (no) | 2001-03-27 |
| AU6087399A (en) | 2000-04-17 |
| CN1328459A (zh) | 2001-12-26 |
| HUP0103459A2 (hu) | 2002-01-28 |
| WO2000018406A1 (en) | 2000-04-06 |
| TR200100863T2 (tr) | 2001-07-23 |
| JP2002525328A (ja) | 2002-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE390135T1 (de) | Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen | |
| ATE371665T1 (de) | Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen | |
| MXPA05013637A (es) | Inhibidores gsk-3 y usos de los mismos. | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| MXPA05009103A (es) | Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios. | |
| DE60118547D1 (de) | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält | |
| ATE324039T1 (de) | Verwendung von spinosad oder einer zusammensetzung enthaltend spinosad | |
| ATE350377T1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
| PL309604A1 (en) | Pharmaceutical composition for treating nicotin dependence | |
| IL151628A0 (en) | Combination therapies with vascular damaging activity | |
| DK1545537T3 (da) | Alfa-7-nikotinreceptoragonister og statiner i kombination | |
| MX2007005065A (es) | Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio. | |
| WO2005039554A3 (en) | Therapeutic use of methionine for the treatment or prevention of mucositis | |
| CY1107231T1 (el) | Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης | |
| TW200509992A (en) | Dosage form containing pantoprazole as active ingredient | |
| WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| AR022621A1 (es) | Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina | |
| BRPI0408500A (pt) | tratamento do diabetes do tipo 1 com inibidores de pde5 | |
| BR9914096A (pt) | Forma de dosagem oral, distinta, método para prevenir ou tratar distúrbio hipercinético de déficit de atenção ou depressão, uso de uma forma de dosagem oral distinta, e, método para tratar vìcio de produtos contendo nicotina | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
| MXPA04004907A (es) | Composiciones de acetaminofen. | |
| WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
| WO2006041769A3 (en) | Methods for the treatment of substance abuse and addiction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |